NextCell Pharma AB (FRA:65G) ROCE %: -87.91% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:65G NextCell Pharma AB FRA:65G
42 GF Score
Price €0.07
GF Value €0.06
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is NextCell Pharma AB ROCE %?

NextCell Pharma AB FRA:65G -5.84% 42 ROCE % is -87.91% as of Dec. 2025. GuruFocus rates FRA:65G with a GF Score™ of 42/100 and a GF Value™ of €0.06 (Modestly Overvalued). The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. NextCell Pharma AB's annualized ROCE % for the quarter that ended in Dec. 2025 was -87.91%.

NextCell Pharma AB  (FRA:65G) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

NextCell Pharma AB ROCE % Related Terms

NextCell Pharma AB ROCE % Historical Data

* Premium members only.

The historical data trend for NextCell Pharma AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NextCell Pharma AB ROCE % Chart

NextCell Pharma AB Annual Data
Trend Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24 Aug25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -27.43 -25.22 -37.74 -56.78 -49.92

NextCell Pharma AB Quarterly Data
Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -47.37 -55.92 -82.79 -58.61 -87.91
FRA:65G
42GF Score
NextCell Pharma AB FRA:65G
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NextCell Pharma AB ROCE % Calculation

NextCell Pharma AB's annualized ROCE % for the fiscal year that ended in Aug. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Aug. 2025 )  (A: Aug. 2024 )(A: Aug. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Aug. 2025 )  (A: Aug. 2024 )(A: Aug. 2025 )
=-3.152/( ( (7.096 - 0.862) + (6.882 - 0.487) )/ 2 )
=-3.152/( (6.234+6.395)/ 2 )
=-3.152/6.3145
=-49.92 %

NextCell Pharma AB's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Aug. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Aug. 2025 )(Q: Dec. 2025 )
=-5.068/( ( (6.882 - 0.487) + (5.873 - 0.738) )/ 2 )
=-5.068/( ( 6.395 + 5.135 )/ 2 )
=-5.068/5.765
=-87.91 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -87.91% mean?
NextCell Pharma AB (FRA:65G) has a ROCE % of -87.91% as of Dec. 2025.
Is NextCell Pharma AB's ROCE % too high?
NextCell Pharma AB's current ROCE % is -87.91%. Overall, NextCell Pharma AB has a GF Score™ of 42/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NextCell Pharma AB's ROCE % compare to VRTX and REGN?
NextCell Pharma AB's ROCE % of -87.91% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. NextCell Pharma AB's current ROCE % is -87.91%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NextCell Pharma AB stock overvalued right now?
Based on GuruFocus' analysis, NextCell Pharma AB (FRA:65G) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.06, compared to a current price of €0.07 — trading 21% above its estimated fair value. The current ROCE % is -87.91%. NextCell Pharma AB's overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For NextCell Pharma AB (FRA:65G), the current ROCE % is -87.91% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NextCell Pharma AB (FRA:65G) Overvalued in 2026?

Based on GuruFocus' analysis, NextCell Pharma AB stock appears to be overvalued. The current stock price of €0.07 is trading 21% above its estimated GF Value™ of €0.06. GuruFocus considers NextCell Pharma AB to be Modestly Overvalued.

Key valuation signals for FRA:65G:

  • ROCE %: -87.91%
  • GF Value™: €0.06 vs. price of €0.07 (21% above fair value)
  • GF Score™: 42/100 with 4 warning signs

No single metric tells the full story. See the FRA:65G stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

NextCell Pharma AB Business Description

Other Exchanges NXTCL:Sweden
Address Karolinska Institutet Science Park, Halsovagen 7, Huddinge, SWE, 14157
NextCell Pharma AB is a healthcare services provider. The company is engaged in the research of stem cell and is developing the candidate drug ProTrans for the treatment of diabetes and immunosuppression in kidney transplants.
42GF Score

Get the complete analysis for FRA:65G

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.07
Price
€0.06
GF Value